Pörssitiedote

Oncopeptides issues warrants to fulfil its obligations under loan agreement with EIB

Oncopeptides AB (publ) (“Oncopeptides”) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the company has resolved on an issue of warrants in order to fulfil Oncopeptides’ obligations under the existing loan agreement with the European Investment Bank (the “EIB”).

Oncopeptides has a contractual obligation to deliver warrants to the EIB upon disbursement of a loan under the renewed loan facility agreement that was entered into with the EIB on 25 November 2022 (the “Loan Agreement”). Under the Loan Agreement, Oncopeptides has delivered in total 2,502,907 warrants to the EIB. According to the terms of the Loan Agreement, the EIB shall be entitled to a percentage of Oncopeptides before and after the rights issue which was completed on 15 September 2025. Existing warrants are recalculated according to the terms of the warrants and Oncopeptides has now issued an additional 285,509 warrants to itself and subsequently transferred 285,509 warrants to the EIB. In total, the EIB holds 2,788,416 warrants which entitle to in total 3,383,326 ordinary shares.

The board of directors of Oncopeptides has issued the warrants based on the authorization granted by the annual general meeting on 22 May 2025. The reason for the deviation from the shareholders’ preferential rights is to enable delivery of warrants to the EIB in accordance with the terms of the Loan Agreement. The warrants have a term of approximately 18 years and entitle the holder to subscribe for new ordinary shares in the company at a subscription price corresponding to the share’s quota value. Upon full subscription of all 2,788,416 warrants currently held by EIB, the company’s registered share capital will increase by approximately SEK 375,925.13 and the number of shares by 3,383,326 ordinary shares.

About Oncopeptides
Oncopeptides is a Swedish biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers.

The company uses its proprietary Peptide Drug Conjugate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East and Africa and elsewhere.

Oncopeptides is also developing several new compounds based on its two proprietary technology platforms PDC and SPiKE.

The company was founded in 2000, has about 80 employees with operations in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO.

For more information see: www.oncopeptides.com

About Pepaxti
Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation.